Seidah
Nabil Seidah, Verdun CA
Patent application number | Description | Published |
---|---|---|
20100310451 | ALTERED N-CADHERIN PROCESSING IN TUMOR CELLS BY FURIN AND PROPROTEIN CONVERTASE 5A (PC5A) - The present invention relates to a method for diagnosis and/or prognosis of cancer and for monitoring the progression of cancer and/or the therapeutic efficacy of an anti-cancer treatment in a subject by determining the molecular form of cadherin at the cell surface of cancer cells in the subject. The invention also relates to a method for preventing, inhibiting or treating cancer or its metastasis in a subject by increasing the adhesive forms of cadherin and/or decreasing the non-adhesive forms of cadherin at the cell surface. The invention also relates to a method step of determining the expression level of furin and proprotein convertase 5A (PC5A). | 12-09-2010 |
Nabil Seidah, Ile Des Soeurs CA
Patent application number | Description | Published |
---|---|---|
20090130691 | SCREENING PROTEINASE MODULATORS USING A CHIMERIC PROTEIN AND SKI-I PROPROTEIN CONVERTASE SUBSTRATES AND INHIBITORS - A chimeric protein comprising in sequence a signal peptide, a first amino acid tag, a proteinase bait, a second amino acid tag, a transmembrane domain and a cytosolic domain, wherein the cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes. A cell line expressing the chimeric protein and an assay using the cell line. | 05-21-2009 |
Nabil G. Seidah, Ile Des Soeurs CA
Patent application number | Description | Published |
---|---|---|
20110003315 | CHIMERIC PCSK9 PROTEINS, CELLS COMPRISING SAME, AND ASSAYS USING SAME - A chimera protein comprising in the following order: a signal peptide, a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9) sequence consisting of amino acid residues at positions 35 to 696 of SEQ ID NO: 38, a transmembrane domain and a cytosolic domain, wherein said cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes. | 01-06-2011 |
20120237945 | CHIMERIC PCSK9 PROTEINS, CELLS COMPRISING SAME, AND ASSAYS USING SAME - A chimera protein comprising in the following order: a signal peptide, a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9) sequence consisting of amino acid residues at positions 35 to 696 of SEQ ID NO: 38, a transmembrane domain and a cytosolic domain, wherein said cytosolic (CT) domain comprises a sequence able to recycle the protein from the cellular membrane to endosomes. | 09-20-2012 |
Nabil G. Seidah, Verdun CA
Patent application number | Description | Published |
---|---|---|
20090104209 | METHODS OF REDUCING A VIRAL INFECTION AND KITS THEREFORE - A method for treating and/or preventing a proprotein convertase subtilisin/kexin type 9 preproprotein (PCSK9)-susceptible viral infection comprising increasing a PCSK9 activity and/or expression in a biological system infected by the virus, whereby the increased PCSK9 activity and/or expression treats and/or prevents the viral infection in the biological system. Methods of classifying subjects, methods of screening and kits therefore. | 04-23-2009 |
20110118181 | PCSK9 INHIBITORS AND METHODS OF USE THEREOF - A method for identifying a compound for preventing or treating a LDLR-associated disease, a VLDLR-associated disease or an ApoER2-associated disease, said method comprising determining whether: a) a level of expression of Annexin A2 nucleic acid or encoded polypeptide; b) a level of Annexin A2 activity; or c) a combination of a) and b), is increased in the presence of a test compound relative to in the absence of said test compound, wherein said increase is indicative that said test compound can be used for preventing or treating a LDLR-associated disease, a VLDLR-associated disease, an ApoER2-associated disease. | 05-19-2011 |
20150017183 | SINGLE DOMAIN ANTIBODIES AS INHIBITORS OF PCSK9 - Antibodies (e.g., sdAbs) binding to PCSK9 are described. Nucleic acids encoding such Abs, host cells expressing such Abs and pharmaceutical composition comprising same are described. The use of these PCSK9-binding Abs for lowering low-density lipoprotein-cholesterol (LDL-C) levels and for the treatment of cardiovascular disorders, is also described. | 01-15-2015 |